LivaNova (LIVN) Income from Continuing Operations (2014 - 2026)
LivaNova (LIVN) reported Income from Continuing Operations of 23145000.0 for Q1 2026, up 107.07% on a YoY basis from 11177301.32 in Q1 2025, and down 25.14% sequentially from 30916000.0 in Q4 2025.
LivaNova (LIVN) Income from Continuing Operations (2014 - 2026) Analysis & Trends
LivaNova (LIVN) has 13 years of Income from Continuing Operations data on file, last reported at 23145000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 107.07% year-over-year to 23145000.0; the trailing twelve-month figure through Mar 2026 stood at 108027000.0 (up 148.63% YoY), and the FY2025 full-year result was 242420000.0, down 483.26% from the prior year.
- Income from Continuing Operations retreated to 23145000.0 in Q1 2026, from 30916000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 55891000.0 in Q4 2024 to a low of 327302000.0 in Q1 2025.
- A 5-year average of 13209764.71 and a median of 16356000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 1283.09% in 2024 and plunged 680.83% in 2025, its largest moves.
- Tracing LIVN's Income from Continuing Operations over 5 years: stood at 1690000.0 in 2022, then jumped by 867.81% to 16356000.0 in 2023, then jumped by 241.72% to 55891000.0 in 2024, then slumped by 44.69% to 30916000.0 in 2025, then declined by 25.14% to 23145000.0 in 2026.
- Business Quant data shows LIVN's Income from Continuing Operations at 23145000.0 in Q1 2026, 30916000.0 in Q4 2025, and 26797000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | LivaNova | 4.30 Bn | 3.76 Bn | 243.75 Mn | 23.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.15 Mn |
| Dec 31, 2025 | 30.92 Mn |
| Sep 30, 2025 | 26.80 Mn |
| Jun 30, 2025 | 27.17 Mn |
| Mar 31, 2025 | -327.30 Mn |
| Dec 31, 2024 | 55.89 Mn |
| Sep 30, 2024 | 32.92 Mn |
| Jun 30, 2024 | 16.36 Mn |
| Mar 31, 2024 | -41.92 Mn |
| Dec 31, 2023 | 16.36 Mn |
| Sep 30, 2023 | -7.29 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 7.40 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | -107.40 Mn |
| Jun 30, 2022 | 16.49 Mn |
| Mar 31, 2022 | 3.03 Mn |
| Dec 31, 2021 | -5.09 Mn |
| Sep 30, 2021 | -43.42 Mn |
| Jun 30, 2021 | -56.45 Mn |